These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

198 related items for PubMed ID: 33838091

  • 1. Bone density and bone health alteration in boys with Duchenne Muscular Dystrophy: a prospective observational study.
    Suthar R, Reddy BVC, Malviya M, Sirari T, Attri SV, Patial A, Tageja M, Didwal G, Khandelwal NK, Saini AG, Saini L, Sahu JK, Dayal D, Sankhyan N.
    J Pediatr Endocrinol Metab; 2021 May 26; 34(5):573-581. PubMed ID: 33838091
    [Abstract] [Full Text] [Related]

  • 2. Bone health measures in glucocorticoid-treated ambulatory boys with Duchenne muscular dystrophy.
    Tian C, Wong BL, Hornung L, Khoury JC, Miller L, Bange J, Rybalsky I, Rutter MM.
    Neuromuscul Disord; 2016 Nov 26; 26(11):760-767. PubMed ID: 27614576
    [Abstract] [Full Text] [Related]

  • 3. Low bone density and bone metabolism alterations in Duchenne muscular dystrophy: response to calcium and vitamin D treatment.
    Bianchi ML, Morandi L, Andreucci E, Vai S, Frasunkiewicz J, Cottafava R.
    Osteoporos Int; 2011 Feb 26; 22(2):529-39. PubMed ID: 20458570
    [Abstract] [Full Text] [Related]

  • 4. Risk factors associated with prevalent vertebral fractures in Duchenne muscular dystrophy.
    Phung K, McAdam L, Ma J, McMillan HJ, Jackowski S, Scharke M, Matzinger MA, Shenouda N, Koujok K, Jaremko JL, Smit K, Walker S, Hartigan C, Khan N, Konji VN, MacLeay L, Page M, Sykes E, Robinson ME, Alos N, Cummings EA, Ho J, Sbrocchi AM, Stein R, Saleh D, Craven BC, Dang UJ, Siminoski K, Rauch F, Ward LM.
    Osteoporos Int; 2023 Jan 26; 34(1):147-160. PubMed ID: 36342539
    [Abstract] [Full Text] [Related]

  • 5. Effectiveness of Neridronate in the Management of Bone Loss in Patients with Duchenne Muscular Dystrophy: Results from a Pilot Study.
    Moretti A, Liguori S, Paoletta M, Gimigliano F, Iolascon G.
    Adv Ther; 2022 Jul 26; 39(7):3308-3315. PubMed ID: 35614293
    [Abstract] [Full Text] [Related]

  • 6. Different bone health progression patterns and early-stage risk marker in glucocorticoid-treated ambulatory Duchenne muscular dystrophy.
    Zhou L, Zhou H, Xu H, Sun X, Chen X, Fan P, Cai X, Wang Q.
    Osteoporos Int; 2024 Jun 26; 35(6):997-1005. PubMed ID: 38277031
    [Abstract] [Full Text] [Related]

  • 7. Bone Mineral Density Assessment by Quantitative Computed Tomography in Glucocorticoid-Treated Boys With Duchenne Muscular Dystrophy: A Linear Mixed-Effects Modeling Approach.
    Liu C, Yang DD, Zhang L, Lei XG, Jia FL, Liao Y, Chen XJ, Ning G, Luo W, Qu HB.
    Front Endocrinol (Lausanne); 2022 Jun 26; 13():860413. PubMed ID: 35399923
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. The time to and determinants of first fractures in boys with Duchenne muscular dystrophy.
    Ma J, McMillan HJ, Karagüzel G, Goodin C, Wasson J, Matzinger MA, DesClouds P, Cram D, Page M, Konji VN, Lentle B, Ward LM.
    Osteoporos Int; 2017 Feb 26; 28(2):597-608. PubMed ID: 27774565
    [Abstract] [Full Text] [Related]

  • 10. Bone health in Duchenne muscular dystrophy: clinical and biochemical correlates.
    Catalano A, Vita GL, Bellone F, Sframeli M, Distefano MG, La Rosa M, Gaudio A, Vita G, Morabito N, Messina S.
    J Endocrinol Invest; 2022 Mar 26; 45(3):517-525. PubMed ID: 34524678
    [Abstract] [Full Text] [Related]

  • 11. Randomized Controlled Trial Evaluating the Use of Zoledronic Acid in Duchenne Muscular Dystrophy.
    Zacharin M, Lim A, Gryllakis J, Siafarikas A, Jefferies C, Briody J, Heather N, Pitkin J, Emmanuel J, Lee KJ, Wang X, Simm PJ, Munns CF.
    J Clin Endocrinol Metab; 2021 Jul 13; 106(8):2328-2342. PubMed ID: 33954789
    [Abstract] [Full Text] [Related]

  • 12. The use of intravenous bisphosphonate therapy to treat vertebral fractures due to osteoporosis among boys with Duchenne muscular dystrophy.
    Sbrocchi AM, Rauch F, Jacob P, McCormick A, McMillan HJ, Matzinger MA, Ward LM.
    Osteoporos Int; 2012 Nov 13; 23(11):2703-11. PubMed ID: 22297733
    [Abstract] [Full Text] [Related]

  • 13. Reduced bone mineral density in adolescents with Duchenne Muscular Dystrophy (DMD) and scoliosis.
    Tsaknakis K, Jäckle K, Lüders KA, Lorenz HM, Braunschweig L, Hell AK.
    Osteoporos Int; 2022 Sep 13; 33(9):2011-2018. PubMed ID: 35583603
    [Abstract] [Full Text] [Related]

  • 14. Effects of Bisphosphonates on Osteoporosis Induced by Duchenne Muscular Dystrophy: A Prospective Study.
    Zheng WB, Dai Y, Hu J, Zhao DC, Wang O, Jiang Y, Xia WB, Xing XP, Li M.
    Endocr Pract; 2020 Dec 13; 26(12):1477-1485. PubMed ID: 33471740
    [Abstract] [Full Text] [Related]

  • 15. Oral bisphosphonate treatment in patients with Duchenne muscular dystrophy on long term glucocorticoid therapy.
    Tian C, Wong BL, Hornung L, Khoury JC, Rybalsky I, Shellenbarger KC, Rutter MM.
    Neuromuscul Disord; 2020 Jul 13; 30(7):599-610. PubMed ID: 32680651
    [Abstract] [Full Text] [Related]

  • 16. Fractures and bone health monitoring in boys with Duchenne muscular dystrophy managed within the Scottish Muscle Network.
    Joseph S, Wang C, Di Marco M, Horrocks I, Abu-Arafeh I, Baxter A, Cordeiro N, McLellan L, McWilliam K, Naismith K, Stephen E, Ahmed SF, Wong SC.
    Neuromuscul Disord; 2019 Jan 13; 29(1):59-66. PubMed ID: 30473133
    [Abstract] [Full Text] [Related]

  • 17. Effect of Testosterone Treatment for Delayed Puberty in Duchenne Muscular Dystrophy.
    Lee SL, Lim A, Munns C, Simm PJ, Zacharin M.
    Horm Res Paediatr; 2020 Jan 13; 93(2):108-118. PubMed ID: 32610327
    [Abstract] [Full Text] [Related]

  • 18. Bone health in boys with Duchenne Muscular Dystrophy on long-term daily deflazacort therapy.
    Mayo AL, Craven BC, McAdam LC, Biggar WD.
    Neuromuscul Disord; 2012 Dec 13; 22(12):1040-5. PubMed ID: 22824639
    [Abstract] [Full Text] [Related]

  • 19. Bone microarchitectural alterations in boys with Duchenne muscular dystrophy on long-term glucocorticoid treatment.
    Tung JY, Lam TP, Chan SH.
    J Bone Miner Metab; 2021 Jul 13; 39(4):606-611. PubMed ID: 33400004
    [Abstract] [Full Text] [Related]

  • 20. Bone density and alendronate effects in Duchenne muscular dystrophy patients.
    Houston C, Mathews K, Shibli-Rahhal A.
    Muscle Nerve; 2014 Apr 13; 49(4):506-11. PubMed ID: 23835890
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.